To better understand the mechanism of drug resistance in TKI-resistant CML patients, the BCR-ABL transformed cell line KCL22 was grown with increasing concentrations of imatinib for a period of 6 weeks. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.